| Outcome Measures: |
Primary: Area under the curve (AUC)0-∞,NNC0519-0130,SD: Area under the NNC0519-0130 plasma concentration-time curve after a single dose in participants with normal function, and mild, moderate and severe impairment, Measured in hours\* nanomoles per litre (h\*nmol/L)., From baseline (visit 2, day 1) until completion of the end-of-study visit (visit 9, day 22) | Secondary: Maximum concentration (Cmax),NNC0519-0130,SD: Maximum observed NNC0519-0130 plasma concentration after a single dose in participants with normal function, and mild, moderate and severe impairment, Measured in nanomoles per litre (nmol/L)., From baseline (visit 2, day 1) until completion of the end-of-study visit (visit 9, day 22)|AUC0-∞,NNC0519-0130,SD: Area under the NNC0519-0130 plasma concentration-time curve after a single dose in participants with kidney failure, Measured in hours\* nanomoles per litre (h\*nmol/L)., From baseline (visit 2, day 1) until completion of the end-of-study visit (visit 9, day 22)|Cmax,NNC0519-0130,SD: Maximum observed NNC0519-0130 plasma concentration after a single dose in participants with kidney failure, Measured in nanomoles per litre (nmol/L)., From baseline (visit 2, day 1) until completion of the end-of-study visit (visit 9, day 22)|Number of adverse events, Number of events., From time of dosing (visit 2, day 1) until end of study (visit 9, day 22)
|
